Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
October 2006
Features
Letter to the Editor
HRT: Natural versus Synthetic
Joe Jeffries, RPh
Costs Associated with Candidemia in a Hospital Setting
The authors conducted a retrospective cohort study at their institution to determine the inpatient care cost of treating candidemia, the leading cause of fungal infections in hospitalized patients.
Joshua J. Gagne, PharmD, Ross E. Breitbart, MS, Vittorio Maio, PharmD, MS, MSPH, David L. Horn, MD, Christine W. Hartmann, MSS, PhD, Robert Swanson, PhD, and Neil I. Goldfarb
Dose–Conversion Ratio for Epoetin Alfa and Darbepoetin Alfa in Chemotherapy Patients with Anemia and Cancer
The authors present the findings of a study that was designed to compare the effectiveness and equivalence of two erythropoietic agents based on a randomized, prospective clinical trial.
Antoine Gosselin, MA, R. Scott McKenzie, MD, Patrick Lefebvre, MA, Samir H. Mody, PharmD, MBA, Catherine Tak Piech, MBA, and
Mei Sheng Duh, MPH, ScD
Continuing Education Credit
Cardiovascular Effects of COX-2 Inhibitors: A Review of the Literature
In multiple trials and analyses, the incidence of cardiovascular events has been higher with coxibs than with placebo and other nonselective NSAIDs. Although an explanation for these events has not yet been determined, several theories relate to physiological mechanisms, drug selectivity or structure, doses and duration of clinical trials, and the influence of underlying disease states.
Craig D. Cox, PharmD, BCPS, Brad L. Stanford, PharmD, BCOP,
James P. Tsikouris, PharmD, Michael J. Peeters, PharmD, BCPS, and Gary Meyerrose, MD
Departments
Editorial
Leadership
David Nash, MD, MBA, illustrates the importance of one executive’s commitment to developing new leaders and emphasizes the need for the health care industry to recognize this challenge.
David Nash, MD, MBA
Prescription: Washington
Drug Pedigrees and Distribution Dilemmas: FDA’s New Requirements May Disrupt Pharmacy–Wholesaler Relationships
Stephen Barlas explains a new FDA anti-counterfeiting measure that will require pharmacies to obtain a drug “pedigree” from wholesalers who are not authorized distributors.
Stephen Barlas
Medication Errors
“Smart” Infusion Pumps Join CPOE and Bar Coding as Ways to Prevent Medication Errors
Matthew Grissinger, RPh, FASCP, discusses the technology of “smart” infusion pumps that will aid hospitals in the effort to reduce mistakes.
Matthew Grissinger, RPh, FASCP
New Drugs/Drug News/New Medical Devices
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
Pregabalin (Lyrica): A New Treatment Option for Neuropathic Pain and Partial Seizures
The authors review pregabalin (Lyrica) for neuropathic pain and partial seizures.
Jason N. Roe, PharmD, Edanai M. Velez, PharmD Candidate, and Jose A. Rey, PharmD
